SRC Mutation is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 13 are open and 2 are closed. Of the trials that contain SRC Mutation and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [5].

SRC Mutation is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain SRC Mutation and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

SRC Mutation is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain SRC Mutation and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

SRC Mutation is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain SRC Mutation and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain SRC Mutation and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain SRC Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain SRC Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain SRC Mutation and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SRC Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SRC Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SRC Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].